Armata Pharmaceuticals Inc
AMEX:ARMP
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
Expanded access: Reported initial outcomes from first seven expanded access patients: 6 of 7 treatment successes (86%) with over 500 doses administered and no treatment-related serious adverse events.
Safety signal: Both AB-SA01 and AB-PA01 were well tolerated in treated patients; one death was judged unrelated to phage therapy.
Regulatory path: Targeting an FDA meeting in mid-2018 to discuss a path to approval and aiming to initiate a Phase 2 or registrational study as early as Q4 2018, pending FDA feedback.
Clinical evidence growth: Additional case presentations accepted at conferences (including UCSD lung transplant case showing IV phage reached and replicated in lung), with more data planned for upcoming medical meetings.
Collaborations and funding: Signed a CRADA with the U.S. Department of Veterans Affairs, a collaborative agreement with Westmead Hospital (Sydney), and was awarded an NIAID Therapeutic Development Services grant for AB-SA01 preclinical work.
Financial position: Cash and cash equivalents were $8.2 million as of March 31, 2018; company believes cash runway extends into Q4 2018 after two financings completed in the period.
Strategic review: Company is exploring pharma partnerships and working with Ladenburg Thalmann on strategic alternatives to maximize shareholder value.
